Promising MS Stem Cell Research Funded by Department of Defense 1:33
National MS Society Announces Strategic Partnership with U.S. Department of Veteran Affairs 4:32
The Risks of Stem Cell Tourism 5:26
Celgene Seeks EMA Approval of Ozanimod 11:29
FDA Approves Esketamine for Treatment-Resistant Depression 12:50
My Interview with Dr. Mitzi Joi Williams 16:27
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes.
Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Phone: (310) 526-2283
If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com
Download the RealTalk MS App for iOS
Download the RealTalk MS App for Android
Give RealTalk MS a Rating & Review
Using Reprogrammed Stem Cells as a Therapy for MS
Complications of Stem Cell Tourism in Multiple Sclerosis & Other Neurological Diseases: Results From First Nationwide Survey of Academic Neurologists
Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
FDA Approves Esketamine Nasal Spray for Treatment of Resistant Depression
MS Made Simple by Dr. Mitzi Joi Williams
Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 82
Hosted By: Jon Strum
Guest: Dr. Mitzi Joi Williams
Tags: MS, MultipleSclerosis, MSResearch, mssociety, Ozanimod, Esketamine, iConquerMS, Stemcells, RealTalkMS